8 results on '"Albert, Gil-Vila"'
Number of results to display per page
Search Results
2. Cancer in myositis
- Author
-
Albert Selva-O'Callaghan, Maria Terrones-Peinador, Joana Rita Marques-Soares, and Albert Gil-Vila
- Subjects
anti-tif1g ,cancer-associated myositis ,dermatomyositis ,immune-mediated necrotizing myopathy ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
There is an intriguing relationship between cancer and myositis. The immunosuppressive agents commonly used to treat myositis patients are known to favor the development of cancer, but this factor does not seem to be the main cause of the association. Most myositis patients who develop cancer are considered to have cancer-associated myositis, which suggests that there are some types of etiopathogenic relationship between these two conditions. The malignancy usually appears within 3 years of the myositis diagnosis, and the risk of cancer depends on the myositis phenotype, with classic or amyopathic dermatomyositis (DM) and immune-mediated necrotizing myopathy being the main associated phenotypes. Several considerations regarding the pathogenesis of this association and strategies to detect occult malignancy in these patients are discussed here, with special emphasis on the role of autoantibodies as markers of this condition. Anti- TIF1g (Transcription Intermediary Factor 1 gamma) antibodies have been extensively studied in patients with cancer-associated DM. In addition, we discuss the peculiarities of treating patients with cancer-associated myositis and suggest some good treatment options, and finally, we examine the cancer–myositis relationship with regard to the recently described concept of myositis as an immune-related adverse event derived from the use of checkpoint immune inhibitors to treat cancer.
- Published
- 2020
- Full Text
- View/download PDF
3. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
- Author
-
Masataka Kuwana, Albert Gil-Vila, and Albert Selva-O’Callaghan
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of ILD involvement in these patients. This review features the role of several autoantibodies as a diagnostic and prognostic biomarker linked to the presence ILD and specific ILD phenotypes in autoimmune rheumatic disorders. The case of the diverse antisynthetase antibodies in the antisynthease syndrome or the anti-melanoma differentiation-associated 5 protein (MDA5) antibodies as a marker of a severe condition such as rapidly progressive ILD in patients with clinically amyopathic dermatomyositis are some of the associations herein reported in the group of myositis spectrum disorders. Specific autoantibodies such as the well-known anti-topoisomerase I (anti-Scl70) or the anti-Th/To, anti-U11/U12 ribonucleoprotein, and anti-eukaryotic initiation factor 2B (eIF2B) antibodies seems to be specifically linked to ILD in patients with systemic sclerosis. Overlap syndromes between systemic sclerosis and myositis, also have good ILD biomarkers, which are the anti-PM/Scl and anti-Ku autoantibodies. Lastly, other not so often reported disorders as being associated with ILD but recently most recognized as is the case of rheumatoid arthritis associated ILD or entities herein included in the miscellaneous disorders section, which include anti-neutrophil cytoplasmic antibody-associated interstitial lung disease, Sjögren’s syndrome or the mixed connective tissue disease, are also discussed.
- Published
- 2021
- Full Text
- View/download PDF
4. COVAD survey 2 long-term outcomes: unmet need and protocol
- Author
-
Zoha Zahid Fazal, Parikshit, Sen, Mrudula, Joshi, Naveen, Ravichandran, Lilleker, James B., Vishwesh, Agarwal, Sinan, Kardes, Minchul, Kim, Jessica, Day, Ashima, Makol, Marcin, Milchert, Tamer, Gheita, Babur, Salim, Tsvetelina, Velikova, Abraham Edgar Gracia-Ramos, Ioannis, Parodis, Elena, Nikiphorou, Ai Lyn Tan, Tulika, Chatterjee, Lorenzo, Cavagna, Saavedra, Miguel A., Samuel Katsuyuki Shinjo, Nelly, Ziade, Albert, Selva-O’Callaghan, Arvind, Nune, Johannes, Knitza, Masataka, Kuwana, Carlos-Enrique Toro Gutiérrez, Carlo Vinicio Caballero-Uribe, Dzifa, Dey, Oliver, Distler, Hector, Chinoy, Vikas, Agarwal, Rohit, Aggarwal, Latika Gupta, COVAD Study Group: Barman, Yogesh Preet Singh, Rajiv, Ranjan, Avinash, Jain, Sapan, C Pandya, Rakesh Kumar Pilania, Aman, Sharma, Manesh Manoj, M, Vikas, Gupta, Chengappa, G Kavadichanda, Pradeepta Sekhar Patro, Sajal, Ajmani, Sanat, Phatak, Rudra Prosad Goswami, Abhra Chandra Chowdhury, Ashish Jacob Mathew, Padnamabha, Shenoy, Ajay, Asranna, Keerthi Talari Bommakanti, Anuj, Shukla, Arun Kumar, R Pandey, Prithvi Sanjeevkumar Gaur, Mahabaleshwar, Mamadapur, Akanksha, Ghodke, Kunal, Chandwar, Kshitij, Jagtap, Döndü Üsküdar Cansu, Reşit, Yıldırım, Aarat, Patel, John, D Pauling, Chris, Wincup, Margherita, Giannini, François, Maurier, Julien, Campagne, Alain, Meyer, Nicoletta Del Papa, Gianluca, Sambataro, Atzeni, Fabiola, Marcello, Govoni, Simone, Parisi, Elena Bartoloni Bocci, Gian Domenico Sebastiani, Enrico, Fusaro, Marco, Sebastiani, Quartuccio, Luca, Franceschini, Franco, Pier Paolo Sainaghi, Giovanni, Orsolini, Rossella De Angelis, Maria Giovanna Danielli, Vincenzo, Venerito, Silvia, Grignaschi, Alessandro, Giollo, Lisa, S Traboco, Syahrul Sazliyana Shaharir, Suryo Anggoro Kusumo Wibowo, Erick Adrian Zamora Tehozol, Jorge Rojas Serrano, Ignacio García-De La Torre, Colunga‑pedraza, Iris J., Javier, Merayo-Chalico, Jesús, Loarce-Martos, Sergio, Prieto-González, Albert, Gil-Vila, Raquel, Aranega, Leonardo Santos Hoff, Ran, Nakashima, Shinji, Sato, Naoki, Kimura, Yuko, Kaneko, Stylianos, Tomaras, Fabian Nikolai Proft, Marie-Therese, Holzer, Margarita Aleksandrovna Gromova, Aharonov, Or, Melinda, Nagy-Vincze, Zoltán, Griger, Ihsane, Hmamouchi, Pr Imane El bouchti, Zineb, Baba, Uyi, Ima-Edomwonyi, Ibukunoluwa, Dedeke, Emorinken, Airenakho, Nwankwo Henry Madu, Abubakar, Yerima, Hakeem, Olaosebikan, Okwara Celestine Chibuzo, Becky, A, Ouma Devi Koussougbo, Elisa, Palalane, Daman, Langguth, Vidya, Limaye, Merrilee, Needham, Nilesh, Srivastav, Marie, Hudson, Océane, Landon-Cardinal, Wilmer Gerardo Rojas Zuleta, Álvaro, Arbeláez, Javier, Cajas, José António Pereira Silva, João Eurico Fonseca, Olena, Zimba, Doskaliuk, Bohdana, Ho, So, Manuel Francisco Ugarte-Gil, Lyn, Chinchay, José Proaño Bernaola, Victorio, Pimentel, Tanveer Hasan, A. T. M., Sreoshy, Saha, Binit, Vaidya, Hanan Mohamed Fathi, Reem Hamdy, A Mohammed, Yi-Ming, Chen, Ghita, Harifi, Lina El Kibbi, Hussein Mohammed Halabi, Akawatcharangura, P, Wanruchada, Katchamart, Yurilís, Fuentes-Silva, Karoll, Cabriza, Jonathan, Losanto, Nelly, Colaman, Antonio, Cachafeiro-Vilar, Generoso Guerra Bautista, Enrique Julio Giraldo Ho, Raúl Agustín González, Lilith Stange Nunez, Cristian Vergara, M, Jossiell Then Báez, Hugo, Alonzo, Carlos Benito Santiago Pastelin, Rodrigo García Salinas, Alejandro Quiñónez Obiols, Nilmo, Chávez, Andrea Bran Ordóñez, Sandra, Argueta, Daniel, Quijivix, Gil Alberto Reyes Llerena, Radames, Sierra-Zorita, Dina, Arrieta, Eduardo Romero Hidalgo, Ricardo, Saenz, Idania Escalante, M., Roberto, Morales, Wendy, Calapaqui, Ivonne, Quezada, Gabriela, Arredondo, Institut Català de la Salut, [Fazal ZZ] Medical College, Aga Khan University Hospital, National Stadium Road, Sindh, Pakistan. [Sen P] Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, India. [Joshi M] Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India. [Ravichandran N] Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. [Lilleker JB] Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. Neurology, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK. [Agarwal V] Mahatma Gandhi Mission Medical College, Navi Mumbai, Maharashtra, India. [Selva-O'Callaghan A] Unitat d’Inflamació i Autoimmunitat, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Autoimmune diseases ,COVID-19 ,Long-term adverse effects ,Registries ,Vaccination ,COVID-19 Vaccines ,COVID-19/prevention & control ,Immunology ,Complex Mixtures::Biological Products::Vaccines::Viral Vaccines [CHEMICALS AND DRUGS] ,Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] ,Enquestes ,Antiviral Agents ,Rheumatology ,Other subheadings::Other subheadings::/adverse effects [Other subheadings] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Immunology and Allergy ,Humans ,Pandemics/prevention & control ,Vacunes - Efectes secundaris ,Pandemics ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,mezclas complejas::productos biológicos::vacunas::vacunas víricas [COMPUESTOS QUÍMICOS Y DROGAS] ,Long term adverse effects ,Covid-19 ,COVID-19 (Malaltia) - Vacunació ,COVID-19 Vaccines/adverse effects - Abstract
COVID-19; Registries; Vaccination COVID-19; Registros; Vacunación COVID-19; Registres; Vacunació Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups. HC is supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
- Published
- 2022
- Full Text
- View/download PDF
5. Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study
- Author
-
Mrinalini, Dey, Naveen, R, Elena, Nikiphorou, Parikshit, Sen, Sreoshy, Saha, James, B Lilleker, Vishwesh, Agarwal, Sinan, Kardes, Jessica, Day, Marcin, Milchert, Mrudula, Joshi, Tamer, Gheita, Babur, Salim, Tsvetelina, Velikova, Abraham Edgar Gracia-Ramos, Ioannis, Parodis, Albert Selva O'Callaghan, Minchul, Kim, Tulika, Chatterjee, Ai Lyn Tan, Ashima, Makol, Arvind, Nune, Lorenzo, Cavagna, Miguel, A Saavedra, Samuel Katsuyuki Shinjo, Nelly, Ziade, Johannes, Knitza, Masataka, Kuwana, Oliver, Distler, Bhupen, Barman, Yogesh Preet Singh, Rajiv, Ranjan, Avinash, Jain, Sapan, C Pandya, Rakesh Kumar Pilania, Aman, Sharma, Manesh, Manoj, Vikas, Gupta, Chengappa, G Kavadichanda, Pradeepta Sekhar Patro, Sajal, Ajmani, Sanat, Phatak, Rudra Prosad Goswami, Abhra Chandra Chowdhury, Ashish Jacob Mathew, Padnamabha, Shenoy, Ajay, Asranna, Keerthi Talari Bommakanti, Anuj, Shukla, Arunkumar, R Pande, Kunal, Chandwar, John, D Pauling, Chris, Wincup, Döndü Üsküdar Cansu, Erick Adrian Zamora Tehozol, Jorge Rojas Serrano, Ignacio García-De La Torre, Nicoletta Del Papa, Gianluca, Sambataro, Fabiola, Atzeni, Marcello, Govoni, Simone, Parisi, Elena Bartoloni Bocci, Gian Domenico Sebastiani, Enrico, Fusaro, Marco, Sebastiani, Quartuccio, Luca, Franceschini, Franco, Pier Paolo Sainaghi, Giovanni, Orsolini, Rossella De Angelis, Maria Giovanna Danielli, Vincenzo, Venerito, Lisa, S Traboco, Leonardo Santos Hoff, Suryo Anggoro Kusumo Wibowo, Stylianos, Tomaras, Daman, Langguth, Vidya, Limaye, Merrilee, Needham, Nilesh, Srivastav, Akira, Yoshida, Ran, Nakashima, Shinji, Sato, Naoki, Kimura, Yuko, Kaneko, Jesús, Loarce-Martos, Sergio, Prieto-González, Albert, Gil-Vila, Raquel Arànega Gonzalez, Hector, Chinoy, Vikas, Agarwal, Rohit, Aggarwal, Latika, Gupta, and COVAD Study Group
- Published
- 2022
6. Cancer in myositis
- Author
-
Maria Terrones-Peinador, Albert Selva-O'Callaghan, Albert Gil-Vila, and Joana Rita Marques-Soares
- Subjects
lcsh:Diseases of the musculoskeletal system ,dermatomyositis ,business.industry ,cancer-associated myositis ,immune-mediated necrotizing myopathy ,Autoantibody ,Cancer ,Dermatomyositis ,medicine.disease ,Malignancy ,anti-tif1g ,Pathogenesis ,Immune system ,Rheumatology ,Immunology ,medicine ,lcsh:RC925-935 ,business ,Adverse effect ,Myositis - Abstract
There is an intriguing relationship between cancer and myositis. The immunosuppressive agents commonly used to treat myositis patients are known to favor the development of cancer, but this factor does not seem to be the main cause of the association. Most myositis patients who develop cancer are considered to have cancer-associated myositis, which suggests that there are some types of etiopathogenic relationship between these two conditions. The malignancy usually appears within 3 years of the myositis diagnosis, and the risk of cancer depends on the myositis phenotype, with classic or amyopathic dermatomyositis (DM) and immune-mediated necrotizing myopathy being the main associated phenotypes. Several considerations regarding the pathogenesis of this association and strategies to detect occult malignancy in these patients are discussed here, with special emphasis on the role of autoantibodies as markers of this condition. Anti- TIF1g (Transcription Intermediary Factor 1 gamma) antibodies have been extensively studied in patients with cancer-associated DM. In addition, we discuss the peculiarities of treating patients with cancer-associated myositis and suggest some good treatment options, and finally, we examine the cancer–myositis relationship with regard to the recently described concept of myositis as an immune-related adverse event derived from the use of checkpoint immune inhibitors to treat cancer.
- Published
- 2020
7. COVID-19 vaccination in autoimmune disease (COVAD) survey protocol
- Author
-
Parikshit, Sen, Latika, Gupta, James, B Lilleker, Vishwesh, Aggarwal, Sinan, Kardes, Marcin, Milchert, Tamer, Gheita, Babur, Salim, Tsvetelina, Velikova, Abraham Edgar Gracia-Ramos, Ioannis, Parodis, Albert Selva O'Callaghan, Elena, Nikiphorou, Ai Lyn Tan, Lorenzo, Cavagna, Miguel, A Saavedra, Samuel Katsuyuki Shinjo, Nelly, Ziade, Johannes, Knitza, Masataka, Kuwana, Giovanni, Cagnotto, Arvind, Nune, Oliver, Distler, Hector, Chinoy, Vikas, Aggarwal, Rohit, Aggarwal, COVAD Study Group COVAD Study Group: Bhupen Barman, Yogesh Preet Singh, Rajiv, Ranjan, Avinash, Jain, Sapan, C Pandya, N Malaviya, A, Rakesh Kumar Pilania, Aman, Sharma, M Manesh Manoj, Vikas, Gupta, Chengappa, G Kavadichanda, Pradeepta Sekhar Patro, Sajal, Ajmani, Sanat, Phatak, Rudra Prosad Goswami, Abhra Chandra Chowdhury, Ashish Jacob Mathew, Padnamabha, Shenoy, Ajay, Asranna, Keerthi Talari Bommakanti, Anuj, Shukla, Naveen, R, Döndü Üsküdar Cansu, John, D Pauling, Chris, Wincup, Tulika, Chatterjee, Minchul, Kim, Margherita, Giannini, Nicoletta Del Papa, Gianluca, Sambataro, Atzeni, Fabiola, Marcello, Govoni, Simone, Parisi, Elena Bartoloni Bocci, Gian Domenico Sebastiani, Enrico, Fusaro, Marco, Sebastiani, Luca, Quartuccio, Franceschini, Franco, Pier Paolo Sainaghi, Giovanni, Orsolini, Rossella De Angelis, Maria Giovanna Danielli, Lisa, S Traboco, Suryo Anggoro Kusumo Wibowo, Jorge Rojas Serrano, Ignacio García-De La Torre, Erick Adrian Zamora Tehozol, Jesús, Loarce-Martos, Sergio, Prieto-González, Albert, Gil-Vila, Raquel, Aranega, Ran, Nakashima, Shinji, Sato, Naoki, Kimura, Yuko, Kaneko, Stylianos, Tomaras, Margarita Aleksandrovna Gromova, and Aharonov, Or
- Subjects
medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Autoimmune diseases ,Immunology ,Disease ,Observational Research ,Rheumatology ,Internal medicine ,Pandemic ,Humans ,Immunology and Allergy ,Medicine ,Intensive care medicine ,Adverse effect ,Survey ,Autoimmune disease ,business.industry ,Vaccination ,COVAD ,COVID-19 ,medicine.disease ,Increased risk ,Health Care Surveys ,Autoimmune Diseases ,Vaccination Hesitancy ,business - Abstract
The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators. Supplementary Information The online version contains supplementary material available at 10.1007/s00296-021-05046-4.
- Published
- 2021
8. PET Scan: Nuclear Medicine Imaging in Myositis
- Author
-
Iago Pinal-Fernandez, Marcelo Alvarado-Cardenas, Albert Selva-O'Callaghan, Marc Simó-Perdigó, Ernesto Trallero-Araguás, Albert Gil-Vila, Johns Hopkins University School of Medicine, Universitat Autònoma de Barcelona, and Universitat Oberta de Catalunya (UOC)
- Subjects
0301 basic medicine ,medicine.medical_specialty ,PET/CT ,Malignancy ,Polymyositis ,Dermatomyositis ,Inflammatory myopathy ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Neoplasms ,Positron Emission Tomography Computed Tomography ,Cancer screening ,medicine ,Humans ,Mass Screening ,Myositis ,030203 arthritis & rheumatology ,Sporadic inclusion body myositis ,PET-CT ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Activity ,030104 developmental biology ,Positron emission tomography ,Radiology ,business - Abstract
Purpose of Review Positron emission tomography (PET) combined with computed tomography (CT) has proven useful as a cancer screening technique in patients with inflammatory myopathy, mainly dermatomyositis. In this review, we focus on advances in this direction and other potential applications of PET/CT in patients with inflammatory myopathy. Recent Findings Cancer screening by PET/CT seems suitable and cost-effective in patients with myositis. It has also shown value as a hybrid technique for diagnosing myositis versus controls and could be of interest for differentiating between polymyositis and sporadic inclusion body myositis. Quantification of muscle activity by PET/CT seems reliable. Preliminary data suggest that it could also be used to diagnose and measure the activity of the disease in the lung. Summary PET/CT should be in the toolbox of physicians managing patients with myositis. The multiple applications of PET/CT include its value for cancer screening, measuring the activity of the disease in muscle, and helping to differentiate between myositis phenotypes. The possibility to diagnose and monitor inflammatory lung activity remains to be demonstrated in welldesigned studies.
- Published
- 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.